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Lipid-lowering therapy and low-density
lipoprotein cholesterol goal attainment
after acute coronary syndrome: a Danish
population-based cohort study
Marie Skov Kristensen1, Anders Green2,3, Mads Nybo4, Simone Møller Hede2, Kristian Handberg Mikkelsen5,
Gunnar Gislason1,6,7,8, Mogens Lytken Larsen9 and Annette Kjær Ersbøll1*
Abstract
Background: Patients with acute coronary syndrome (ACS) are at high risk of recurrent cardiovascular (CV) event.
The European guidelines recommend low-density lipoprotein cholesterol (LDL-C) levels < 1.8 mmol/L and early
initiation of intensive lipid-lowering therapy (LLT) to reduce CV risk.
In order to reduce the risk of further cardiac events, the study aimed to evaluate LDL-C goal attainment and LLT
intensity in an incident ACS population.
Methods: A cohort study of patients with residency at Funen in Denmark at a first-ever ACS event registered
within the period 2010–2015. Information on LLT use and LDL-C levels was extracted from national population
registers and a Laboratory database at Odense University Hospital. Treatments and lipid patterns were evaluated
during index hospitalization, at 6-month and 12-month follow-up.
Results: Among 3040 patients with an LDL-C measurement during index hospitalization, 40.7 and 39.0% attained
the recommended LDL-C target value (< 1.8 mmol/L) within 6- and 12-month follow-up, respectively. During 6- and
12-month follow-up, a total of 89.2% (20.2%) and 88.4% (29.7%) used LLT (intensive LLT). Of the intensive LLT users,
43.4 and 47.7% reached the LDL-C target value at 6- and 12-month follow-up. The frequency of lipid monitoring
was low: 69.5, 77.7 and 53.6% in patients with a first-ever ACS during index hospitalization, 6- and 12-month follow-
up, respectively.
Conclusion: Using national health registers and laboratory data, a considerably gap was observed between treatment
guidelines and clinical practice in the management of dyslipidemia leaving very high-risk patients without adequate
lipid management strategy. Therefore, improved lipid management strategies aimed at reaching treatment targets are
warranted.
Keywords: Low-density lipoprotein cholesterol, LDL-C goal attainment, Dyslipidemia, Lipid-lowering therapy, Acute
coronary syndrome, Population-based individual-level registers
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Background
Patients surviving an acute coronary syndrome (ACS) (i.e.
diagnosis of acute myocardial infarction (AMI) or unstable
angina (UA)) have an increased risk of recurrent cardio-
vascular (CV) events [1]. Early multidisciplinary cardiac
rehabilitation to improve risk factors, e.g. smoking cessa-
tion, lifestyle advice and lipid profile modification is asso-
ciated with reduced CV mortality [2].
In the management of dyslipidemia, it is well-established
that lowering low-density lipoprotein cholesterol (LDL-C)
concentration among very high-risk patients is the primary
target to reduce the risk of CV events [3]. Until recently, the
European clinical guidelines treatment goal for very high-risk
patients was LDL-C< 1.8mmol/L (< 70mg/dL) or at least a
50% reduction in LDL-C if the baseline LDL-C was between
1.8–3.5mmol/L [3]. According to current 2019 guidelines,
the treatment goal is reduced to LDL-C< 1.4mmol/L,
which will cause even more attention on intensive LLT [4].
Today, ACS patients are already recommended to initiate
high-intensity lipid-lowering therapy (LLT), mainly statins
and/or combinational therapy, within the first 1–4 days of
hospitalization [3, 5]. Yet, despite treatment with standard
LLT, many European patients at very high risk of CV disease
continue to have poorly controlled LDL-C levels and persist-
ently high risk of recurrent CV events [6–8].
Statins are established as first-line LLT in ACS pa-
tients but novel agents for managing dyslipidemia are
now available, such as proprotein convertase subtilisin-
kexin type 9 (PCSK9) inhibitors. When guiding treat-
ment decision for new LLTs in clinical practice it is
valuable to gain insight into current treatment practice
of dyslipidemia management.
Using Danish population-based health registers linked
to clinical laboratory data, it is possible to provide infor-
mation on lipid measurements and drug use at an indi-
vidual level in a representative sample of the Danish
population. In order to reduce the risk of further cardiac
events, the aim of this study was to evaluate LDL-C goal
attainment and the pattern of LLT use by intensity in
patients with incident (first-ever) ACS.
Methods
Study design and setting
This is a population-based cohort study of the Funen
population conducted in the study period January 1,
2010 to December 31, 2015. The population consists of
approximately 0.5 million citizens (Q4 2018: 498,601 cit-
izens) corresponding to 9% of the Danish population.
The Region of Southern Denmark is a representative
sample of the entire Danish population [9], which also
applies to Funen [10]. The Danish healthcare system is
tax-financed providing free access to treatment at hospi-
tals and general practitioners. Most prescription drugs
are covered by a reimbursement system applying for Da-
nish citizens buying medication from a pharmacy [11].
ACS and study population
Patients were eligible for inclusion if they 1) had experi-
enced their first-ever qualifying ACS event within the
study period (referred to as index hospitalization) and 2)
had residency at Funen during index hospitalization.
This comprised the ACS population.
Patients fulfilling the abovementioned criteria with at
least one LDL-C measurement before or during index
hospitalization (i.e., from 2 days before admission until
discharge) identified in the laboratory database of Odense
University Hospital, comprised the study population. Pa-
tients dying within 28 days after index hospitalization were
excluded from the study.
ACS was identified in the Danish National Patient
Register [12, 13] and defined as either a) primary diag-
nosis of AMI or b) a primary diagnosis of UA together
with a primary procedure code of coronary angiography
(CAG) during the same index hospitalization (see Add-
itional file 1 for codes). Patients with a diagnosis of ACS
in the period 1977–2009 were excluded to ascertain
truly first-ever cases. In case of two CV events occurring
at the same date, AMI events were registered and over-
ruling any registration of UA with CAG. The positive
predictive value for ACS diagnosis identified in the Da-
nish National Patient Register is high (86.6%) [14].
Data sources
Data sources comprised the Danish National Prescrip-
tion Register, the Danish National Patient Register, and
the Laboratory databases of Odense University Hospital.
Individual-level linkage was facilitated by use of the
unique civil registration number (CPR number) assigned
to all individuals with permanent residence in Denmark
at birth or immigration by the Danish Civil Registration
System [15].
Lipid measurements
Blood samples collected by general practitioners and at
hospital wards at Funen were analyzed at hospital-based
laboratories in the Funen County in the entire study
period. Test results were stored in the Netlab Database
until February 23, 2013 and in BCC from February 24,
2013 until the end of the study period. Data on lipid
measurements were extracted from these databases with
information on CPR number, test results of LDL-C,
high-density lipoprotein cholesterol (HDL-C), total chol-
esterol and triglycerides, and the date of testing. Total
cholesterol, HDL-C and triglycerides were measured in
lithium-heparin plasma using an Architect c16000
analyzer (Abbott) with dedicated reagents, while LDL-C
was calculated using Friedewald’s formula [16], when
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plasma triglycerides were ≤ 4 mmol/L (354 mg/dL),
otherwise a direct plasma LDL-C measurement was per-
formed with the same Abbott analyzer.
Lipid-lowering therapy
Data on redeemed prescriptions of LLT were extracted
from the Danish National Prescription Register [17],
which contains data on all prescriptions redeemed at
Danish pharmacies since 1995. Information on CPR
number, the date of drug dispensing and administration
of study drug using the Anatomical Therapeutic Chem-
ical (ATC) classification codes were extracted from the
register (see Additional file 1 for ATC codes). A total of
99% of the sale of lipid-modifying agents (ATC: C10)
registered in the Danish National Prescription Registry
was person-identifiable [18].
Demographic and clinical characteristics
Information on the ACS population at index hospitalization
on age, sex, cohabitation status and ethnicity was extracted
from The Danish Civil Registration System. The mean an-
nual disposable household income was extracted from Da-
nish income registers at Statistics Denmark [19] 1 year prior
to index hospitalization as a proxy measure for socioeco-
nomic status. Information on comorbidity (chronic kidney
disease and diabetes mellitus) was extracted five-year prior to
index hospitalization. Chronic kidney disease was defined as
either the first occurrence of a primary or secondary diagno-
sis or the first occurrence of a kidney transplantation identi-
fied in the Danish National Patient Register. Diabetes
Mellitus Type 1 or 2 was defined as either the first occur-
rence of a primary or secondary diagnosis identified in the
Danish National Patient Register or the first occurrence of a
prescription redemption with antidiabetic drugs identified in
the Danish National Prescription Register. See Additional file
1 for codes.
Variable definitions
Low-density lipoprotein cholesterol
It is recommended to use LDL-C as the primary target
to manage dyslipidemia when initiating and adjusting
LLT [3]. LDL-C measurements were described prior to
index hospitalization (i.e. from 545 days until 3 days be-
fore index hospitalization), during index hospitalization
(i.e. from 2 days before index date until discharge) al-
though a mean lowering of total cholesterol and LDL-C
is well known between day 1 and days 2–4 [20], at 6-
month follow-up (i.e. from discharge to 180 days after
discharge), and at 12-month follow-up (i.e. from 181 days
to 365 days after discharge) (Additional file 2). In case of
more than one LDL-C measurement within the defined
time windows, the LDL-C measurement closest to index
hospitalization, 6-month and 12-month follow-up was
used. For baseline characteristics, the ACS population
was grouped into LDL-C < 1.8 mmol/L; LDL-C ≥ 1.8
mmol/L; and no LDL-C measurement.
Lipid-lowering therapy
The LLT prescription redemption pattern was described
prior to index hospitalization (i.e. the latest prescription
of LLT redeemed from − 180 days until − 3 days before
index hospitalization), during index hospitalization (i.e.
between index hospitalization until 30 days after dis-
charge), at 6-month.follow up (i.e. between 31 days and
180 days after discharge), and at 12-month follow-up (i.e.
between 181 days and 365 days after discharge) (Add-
itional file 2).
LLT was categorized by intensity as “No LLT”, “Mod-
erate LLT” or “Intensive LLT” [3, 21]. “Intensive LLT”
was defined as having 1) a minimum of 2 prescription
redemptions of one combination drug (statins in com-
bination with Ezetimibe); or 2) a minimum of 2 prescrip-
tion redemptions of statins (80 mg Simvastatin, 40–80
mg Atorvastatin or 20–40 mg Rosuvastatin); or 3) a
minimum of 2 prescription redemptions of statins (all
dose and types of statins) and one Ezetimibe prescrip-
tion redemption; or 4) a minimum of 2 statins prescrip-
tion redemptions and one other non-statin (i.e. not
Ezetimibe, Evolocumab and Alirocumab) prescription
redemption. “Moderate LLT” was defined as patients
who were treated with LLT but were not eligible for the
group of “Intensive LLT” or “No LLT”.
Statistical analyses
Mean (standard deviations) or median (interquartile
range) were reported for continuous variables and num-
bers and percentages for categorical variables. All pa-
tients were followed from inclusion (date of admission
with first-ever ACS diagnosis) in 2010–2015 until death,
end of study, or a new cardiac event, whichever came
first. A new cardiac event was defined as a) primary or
secondary diagnosis of AMI, b) a primary or secondary
diagnosis of ischemic stroke, c) a primary diagnosis of
UA together with a primary procedure code of CAG
during the same index hospitalization, d) a primary diag-
nosis of stable angina together with a primary procedure
code of CABG or PCI during the same index
hospitalization, or e) a primary diagnosis or procedure
code of peripheral arterial disease (see Additional file 1
for codes).
All analyses were conducted using SAS software ver-
sion 9.4.
Results
A total of 4646 patients were registered with a first-ever
diagnosis of ACS within the study period (Fig. 1). Pa-
tients with an invalid CPR number or without residency
at Funen at the year of index hospitalization (n = 269)
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were excluded. Of the remaining 4377 patients (i.e., ACS
population), 3040 (69.5%) had at least one LDL-C meas-
urement during index hospitalization (Table 1). Of
those, 153 patients died within 28 days after index
hospitalization leaving 2887 patients for inclusion as the
study population in the analysis (Fig. 1).
Baseline demographic and clinical characteristics
During index hospitalization, 1337 (30.5%) patients had
no LDL-C measurement. Among patients with an LDL-
C measurement during index hospitalization, LDL-C
was above target value (1.8 mmol/L) for 89.4% of the pa-
tients (2718 / (2718 + 322)). The most common index
hospitalization was AMI (88.9%). Patients with no LDL-
C measurement during index hospitalization (71.8 ±
13.3 years) were on average 1.4 and 6.3 years older than
patients with an LDL-C < 1.8 mmol/L (70.4 ± 11.9 years)
and LDL-C ≥ 1.8 mmol/L (65.5 ± 13.3 years), respectively.
Further, more females (43.8% vs. 33.1%) and fewer co-
habitants (51.5% vs. 59.3%) were represented among pa-
tients with no LDL-C measurement compared with
patients with an LDL-C measurement (Table 1).
Fig. 1 Flow diagram illustrating the construction of the ACS population and the study population (January 1, 2010 to December 31, 2015) based
on data from nation-wide population registers. ACS, acute coronary syndrome; CPR, unique personal identification number; LDL-C, low-density
lipoprotein cholesterol; Index hospitalization, hospitalization with incident ASC diagnosis
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Table 1 Baseline characteristics of the ACS population stratified by low-density lipoprotein cholesterol (LDL-C) (LDL-C < 1.8 mmol/L,
LDL-C ≥ 1.8 mmol/L, no measurement) given by number and percentage (N, %) if nothing else is indicated (1 January 2010–31
December 2015)
Variable ACS population, N = 4377
N (%) LDL-C (mmol/L) during index hospitalizationa
Total < 1.8 ≥ 1.8 No
Overall 4377 322 (7.4) 2718 (62.1) 1337 (30.5)
ACS at index date
AMI 3891 (88.9) 275 (85.4) 2530 (93.1) 1086 (81.2)
UA + CAG 486 (11.1) 47 (14.6) 188 (6.9) 251 (18.8
Age, mean ± SD 67.8 ± 13.6 70.4 ± 11.9 65.5 ± 13.4 71.8 ± 13.3
Age groups
< 40 73 (1.7) 5 (1.6) 58 (2.1) 10 (0.7)
40–49 366 (8.4) 8 (2.5) 295 (10.9) 63 (4.7)
50–59 775 (17.7) 42 (13.0) 558 (20.5) 175 (13.1)
60–69 1126 (25.7) 88 (27.3) 718 (26.4) 320 (23.9)
70–79 1067 (24.4) 103 (32.0) 622 (22.9) 342 (25.6)
≥ 80 970 (22.2) 76 (23.6) 467 (17.2) 427 (31.9)
Gender
Male 2787 (63.7) 219 (68.0) 1816 (66.8) 752 (56.2)
Female 1590 (36.3) 103 (32.0) 902 (33.2) 585 (43.8)
Cohabitation
Yes 2490 (56.9) 191 (59.3) 1611 (59.3) 688 (51.5)
No 1887 (43.1) 131 (40.7) 1107 (40.7) 649 (48.5)
Ethnicity
Denmark 4101 (93.7) 305 (94.7) 2533 (93.2) 1263 (94.5)
Western 106 (2.4) < 5 70 (2.6) < 35
Non-western 170 (3.9) < 15 115 (4.2) < 45
Comorbidity
Diabetes mellitus 735 (16.8) 128 (39.8) 324 (11.9) 283 (21.2)
Chronic Kidney disease 183 (4.2) 22 (6.8) 82 (3.0) 79 (5.9)
Socioeconomic position
< 100,000 DKK 432 (9.9) 37 (11.5) 257 (9.5) 138 (10.3)
100,000 – 299,999 3497 (79.9) 261 (81.1) 2134 (78.5) 1102 (82.4)
≥ 300,000 448 (10.2) 24 (7.5) 327 (12.0) 97 (7.3)
LLTb before or during index hospitalization
Statins 1338 (30.6) 233 (72.4) 608 (22.4) 497 (37.2)
Ezetimibe 21 (0.5) < 5 16 (0.6) < 5
Other non-statins 13 (0.3) < 5 6 (1.9) < 10
Combinational treatment 15 (0.3) < 10 6 (1.9) < 5
No treatment 2990 (68.3) 79 (24.5) 2082 (76.6) 829 (62.0)
LLT intensityb before or during index hospitalization
No LLT 2990 (68.3) 79 (24.5) 2082 (76.6) 829 (62.0)
Moderate LLTc 1262 (28.8) 220 (68.3) 579 (21.3) 463 (34.6)
Intensive LLTd 125 (2.9) 23 (7.1) 57 (2.1) 45 (3.4)
Lipid measurements before index hospitalizatione, N (%), mean ± SD
LDL-C 2967 (67.8) 272 (84.5) 1733 (63.8) 962 (72.0)
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LLT utilization and LDL-C levels prior to index
hospitalization
Less than a third (31.7%) of the ACS population were
registered with an LLT prescription redemption before
index hospitalization. Among patients with an LDL-C <
1.8 mmol/L during index hospitalization, 75.4% were in
LLT prior to index hospitalization including 7.1% being
intensive users.
Among patients with an LDL-C ≥ 1.8 mmol/L, 23.4%
were treated with LLT including 2.1% in intensive LLT.
The preferred LLT was statins. Prior to index
hospitalization, 84.5% of patients with an LDL-C < 1.8
mmol/L during index hospitalization, 63.8% of patients
with an LDL-C ≥ 1.8 mmol/L and 72.0% of patients with
no LDL-C had obtained a lipid profile. The mean (SD)
LDL-C prior to index hospitalization was distributed as
follows according to levels of LDL-C during index
hospitalization: LDL-C < 1.8 mmol/L (1.86 ± 0.68); LDL-
C ≥ 1.8 mmol/L (3.22 ± 1.04); and no measurement
(2.80 ± 1.14) (Table 1).
LLT utilization and LDL-C goal attainment at follow-up
Among the ACS population with at least one LDL-C
measurement during index hospitalization and alive 28
days after index hospitalization (n = 2887), 2242 (77.7%)
had at least one LDL-C measurement registered at 6-
month follow-up and 1547 (53.6%) had at least one
LDL-C measurement registered at 12-month follow-up
(Fig. 1).
During hospitalization, only 7.2% of the patients diag-
nosed with ACS initiated or continued intensive LLT
treatment. In total, 76.4% of the patients initiated or
continued moderate LLT treatment. Although the
proportion of ACS patients treated with intensive LLT
increased during follow-up, only a minority of the pa-
tients were treated with intensive LLT as recommended
in guidelines (20.2 and 29.7% at 6- and 12-month
follow-up). During follow-up, LDL-C goal ascertainment
(LDL-C < 1.8 mmol/L) increased from 10.6% during
index hospitalization to 40.7 and 39.0% during 6- and
12-month follow-up leaving about 60% of the ACS pa-
tients with lack of goal ascertainment (Fig. 2).
6-month follow-up
Among those with a 6-month LDL-C measurement, 912
patients (40.7%) attained LDL-C < 1.8 mmol/L. A total of
2069 (92.3%) used LLT (8.1% intensive LLT) before or
during index hospitalization. Among those with an LDL-
C < 1.8 mmol/L at 6-month follow-up, 42.4 and 42.5%
were treated with moderate or intensive LLT (Table 2).
Among those who continued using LLT at 6-month
follow-up (94.0%, including 21.5% intensive users), the
proportion of moderate and intensive LLT users reach-
ing LDL-C < 1.8 mmol/L remained unchanged (42.9 and
43.4%). Among those who used LLT before or during
index hospitalization, 5.9% had discontinued LLT during
6-month follow-up, among these 66.7% with an LDL-
C ≥ 1.8 mmol/L (Table 2).
12-month follow-up
Among those with a 12-month LDL-C measurement,
604 patients (39.0%) had achieved LDL-C. < 1.8 mmol/L.
Among patients using LLT at 6-month follow-up, 95.2%
continued using LLT at 12-month follow-up (62.8% with
moderate LLT and 32.4% with intensive LLT). Of the
Table 1 Baseline characteristics of the ACS population stratified by low-density lipoprotein cholesterol (LDL-C) (LDL-C < 1.8 mmol/L,
LDL-C ≥ 1.8 mmol/L, no measurement) given by number and percentage (N, %) if nothing else is indicated (1 January 2010–31
December 2015) (Continued)
Variable ACS population, N = 4377
N (%) LDL-C (mmol/L) during index hospitalizationa
Total < 1.8 ≥ 1.8 No
2.96 ± 1.12 1.86 ± 0.68 3.22 ± 1.04 2.80 ± 1.14
HDL-C 2968 (67.8)
1.33 ± 0.43
272 (84.5)
1.32 ± 0.48
1734 (63.8)
1.31 ± 0.39
962 (72.0)
1.37 ± 0.47
Total cholesterol 2995 (68.4)
5.07 ± 1.28
272 (84.5)
3.97 ± 0.91
1750 (64.4)
5.33 ± 1.20
973 (72.8)
4.92 ± 1.31
Triglycerides 2968 (67.8)
1.80 ± 1.23
272 (84.5)
1.84 ± 1.43
1734 (63.8)
1.86 ± 1.28
962 (72.0)
1.69 ± 1.07
ACS Acute coronary syndrome; AMI Acute myocardial infarction; UA unstable angina; CAG Coronary angiography; LLT Lipid-lowering treatment; LDL-C Low-density
lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; SD Standard deviation
a Index hospitalization from 2 days before index date until discharge
b LLT initiated before or during index hospitalization: LLT redeemed −180 prior admission to 30 days
after discharge
c Patients who are treated with LLT, but who are not eligible for the group of “intensive treatment” or “no LLT” treatment
d Intensive LLT is defined by 1) A minimum of 2 prescription redemptions of one combination drug; OR 2) A minimum of 2 statins prescription redemptions; OR 3)
A minimum of 2 statin prescription redemptions and one ezetimibe prescription redemption; OR 4) A minimum of 2 statin prescription redemptions and one
other non-statin (i.e. not ezetimibe) prescription redemption
e Lipid measurements prior index hospitalization: from −545 days to −3 days before index hospitalization
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moderate and intensive LLT users, 39.8 and 47.7% had
achieved LDL-C < 1.8 mmol/L, respectively.
Among patients with LLT during 6-month follow-up
and with moderate or intensive LLT at 12-month
follow-up, a total of 60.2 and 52.3% had an LDL-C ≥ 1.8
mmol/L at 12-month follow-up. For comparison, among
patients with or without LLT during 6-month follow-up
and no LLT at 12-month follow-up, a total of 80.3 and
86.7% had an LDL-C ≥ 1.8 mmol/L at 12-month follow-
up (Table 2).
Stratified by comorbidity (diabetes mellitus and/or
chronic kidney disease)
Among the ACS population with at least one LDL-C
measurement during index hospitalization and alive 28
days after index hospitalization (n = 2887), a total of
16.5% had diabetes mellitus and/or chronic kidney dis-
ease at inclusion. At index hospitalization, 24.2% of the
patients with a comorbidity had an LDL-C < 1.8 mmol/L
as compared to 7.8% among patient without a comorbid-
ity at index hospitalization (Table 3). A larger proportion
of patients with comorbidity obtained LDL-C goal at-
tainment during 6- and 12-month follow-up as com-
pared to patients without a comorbidity (49.7% versus
38.7% at 6-month follow-up and 51.8% versus 36.5% at
12-month follow-up).
Discussion
ACS patients are recommended to initiate intensive
LLT. However, using complete population-based health
registers linked to clinical laboratory data, this study
provided important insight into management of dyslipid-
emia among ACS patients in Denmark and highlights a
considerable gap between recommendation in treatment
guidelines (2016) [3] and clinical practice. We found that
the LDL-C goal attainment was low at 6- and 12-month
follow-up, respectively. Most of the study population
used LLT, but only a minority used intensive LLT as
recommended throughout follow-up. Improvement in
LLT management in this high-risk population is needed.
A larger proportion of the ACS patients with a comor-
bidity had LDL-C < 1.8 mmol/L at index hospitalization
and a larger proportion obtained LDL-C goal attainment
at 6- and 12-month follow-up.
LDL-C goal attainment
According to treatment guidelines [3] it is recommended
that patients at very high risk of a CV event should
achieve LDL-C < 1.8 mmol/L [3]. Moreover, the national
quality indicators of cardiac rehabilitation in Denmark
states that ≥70% of patients with ischemic heart disease
should reach the LDL-C target value < 1.8 mmol/L at the
end of a rehabilitation program [22]. However, in this
study the LDL-C goal attainment was low with less than
half of the study population achieving LDL-C < 1.8
mmol/L at 6- and 12-month follow-up. Treatment with
LLT increased the likelihood of reaching the target value
of LDL-C < 1.8 mmol/L compared with no LLT use. Yet,
the proportion reaching the target value did not differ
substantially between moderate and intensive LLT users
during index hospitalization and 6-month follow-up, but
the likelihood of achieving LDL-C < 1.8 mmol/L at 12-
month follow-up was higher among intensive LLT users
compared with moderate LLT users. Similar findings
were demonstrated in the Netherlands among 2431 hos-
pitalized ACS patients where no substantial difference in
Fig. 2 Distribution of intensive lipid-lowering treatment (LLT) and low-density lipoprotein cholesterol (LDL-C) goal ascertainment (LDL-C < 1.8
mmol/L) in patients diagnosed with acute coronary syndrome (ACS) with an LDL-C measurement during ACS hospitalization (N = 3040), 6-month
(N = 2242) and 12-month follow-up (N = 1547)
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the proportion of patients achieving LDL-C goal was
seen irrespective of treatment with statins plus ezetimibe
or statin as monotherapy [7]. In general, poor LDL-C
goal attainment have been reported in several European
studies among patients hospitalized for ACS (18.9–55%)
[7, 8, 23–25]. It is well-documented that lowering LDL-C
in very-high risk patients have direct cardiovascular bene-
fits. A meta-analysis of 26 randomized trials demonstrated
a decrease of major CV events by 22% for each mmol/L
reduction in LDL cholesterol [26]. Attending a multidis-
ciplinary cardiac rehabilitation program targeting
improvement in LDL-C levels is associated with reduced
risk of morbidity and mortality in patients with ACS [3].
Despite this, it is documented that cardiac rehabilitation is
underused in Europe and the US [27] including Denmark
with only 61% of ACS patients attending a cardiac re-
habilitation program [28].
LLT utilization
We observed that only a third were on LLT prior to
first-ever ACS diagnosis indicating an unmet need for
identifying patients with a high-risk cardiovascular
Table 2 Distribution of the study population by lipid-lowering therapy (LLT) intensity initiated during hospitalization, at 6-month
and 12-month follow-up, and low-density lipoprotein cholesterol (LDL-C) goal attainment at 6-month and 12-month follow-up (1
January 2010–31 December 2015)
LDL-C (mmol/L)
6-month follow-upd (N = 2242) 12-month follow-upe (N = 1547)
LLT Total < 1.8 ≥1.8 Total < 1.8 ≥1.8
Before or during index hospitalizationa 2242 912 (40.7) 1330 (59.3) 1547 604 (39.0) 943 (61.0)
None 173 (7.7) 34 (19.7) 139 (80.3) 122 (7.9) 25 (20.5) 97 (79.5)
Moderateb 1888 (84.2) 801 (42.4) 1087 (57.6) 1282 (82.9) 519 (40.5) 763 (59.5)
Intensivec 181 (8.1) 77 (42.5) 104 (57.5) 143 (9.2) 60 (42.0) 83 (58.0)
LLT
Before or during index
hospitalizationa
6-month follow-
up
None None 120/173 (69.4) 17/120 (14.2) 103/120
(85.8)
89/122 (73.0) 11/89 12.4) 78/89 (87.6)
Moderateb 46/173 (26.6) < 15 < 35 28/122 (23.0) < 15 < 20
Intensivec 7/173
(4.0)
< 7 < 7 5/122 (4.1) < 5 < 5
Yes None 123/2069 (5.9) 41/123 (33.3) 82/123 (66.7) 72/1425 (5.1) 19/72 (26.4) 53/72 (73.6)
Moderateb 1501/2069
(72.5)
644/1501
(42.9)
857/1501
(57.1)
1041/1425
(73.1)
425/1041
(40.8)
616/1041
(59.2)
Intensivec 445/2069
(21.5)
193/445
(43.4)
252/445
(56.6)
312/1425
(21.9)
135/312
(43.3)
177/312
(56.7)
LLT
6-month follow-up 12-month follow-
up
None None – – – 113/161 (70.2) 15/113 (13.3) 98/113 (86.7)
Moderateb – – – 38/161 (23.6) < 15 < 30
Intensivec – – – 10/161 (6.2) < 5 < 10
Yes None – – – 66/1386 (4.8) 13/66 (19.7) 53/66 (80.3)
Moderateb – – – 871/1386
(62.8)
347/871
(39.8)
524/871
(60.2)
Intensivec – – – 449/1386
(32.4)
214/449
(47.7)
235/449
(52.3)
a LLT initiated before or during index hospitalization: LLT redeemed −180 before admission to 30 days
after discharge
b Patients who are treated with LLT, but who are not eligible for the group of “intensive treatment” or “no LLT” treatment
c Intensive LLT is defined by 1) A minimum of 2 prescription redemptions of one combination drug; OR 2) A minimum of 2 statins prescription redemptions; OR 3)
A minimum of 2 statin prescription redemptions and one ezetimibe prescription redemption; OR 4) A minimum of 2 statin prescription redemptions and one
other non-statin (i.e. not ezetimibe) prescription redemption
d LDL-C at 6-month follow-up: LDL-C between discharge and 180 days post discharge from hospital with ACS
e LDL-C at 12-month follow-up: LDL-C between 181 and 365-days post discharge from hospital with ACS
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profile who potentially may benefit from primary pre-
vention in terms of early initiation of LLT [29]. Yet, a
high rate of LLT utilization was observed among the
study population after being diagnosed with ACS. A
similar high LLT use among ACS patients has been
reported in previously studies (at admission: 90.7 and
96.6%, at 120-days follow-up: 85.9 and 96.6%) [24,
25]. Despite this, we found that only few were treated
with intensive LLT throughout the study period,
which is in discordance with the treatment guidelines
recommending initiation of intensive LLT immediately
regardless of baseline cholesterol levels until treat-
ment goal attainment [3]. Evidence has shown that,
intensive LLT reduces the risk of non-fatal and fatal
cardiovascular events to a greater extent than low-to-
moderate LLT [30].
Our result is consistent with existing studies, demon-
strating underutilization of intensive LLT among very
high-risk patients in several European countries. For ex-
ample, a large study (EUROSPIRE IV) conducted among
24 European countries found that 37.6% were discharged
for coronary artery disease with high intensive statin de-
creasing to 32.7% high-intensive users at 6-month
follow-up [31].
Another important finding is that a large proportion
of intensive users failed to reach LDL-C treatment goal.
In this study, intensive LLT was mainly driven by statins
with a smaller proportion using combinational therapy
e.g. statins plus ezetimibe. As prescribed in the
treatment guidelines [3], patients with statin intolerance
should be offered add-on treatment in terms of Ezeti-
mibe and in patients not reaching the recommended
LDL-C target despite maximally tolerated dose PCSK9
inhibitors might be considered. Our finding of a low
proportion of patients reaching LDL-C target level align
with the findings of a recent cohort study from another
part of Denmark [32]. However, the two studies differ
on two important aspects, the study population and aim
of the studies. Sundbøll et al. [32] included a population
of individuals with a prevalent atherosclerotic cardiovas-
cular disease (ASCVD), having an LDL-C ≥ 1.8 mmol/L
and using LLT (statins or ezetimibe). The aim of their
study was to estimate cardiovascular event rates. They
also reported patterns of LLT and LDL-C levels during
follow-up. In the present study, we included a popula-
tion of patients with a first-ever incident ACS. In order
to reduce the risk of further cardiac events, LLT initi-
ation is very important in order to obtain LDL-C goal at-
tainment with LDL-C reduced to a value below 1.8
mmol/L. Therefore, our aim was to evaluate and exam-
ine LDL-C goal attainment and patterns of LLT use in
this population of patients presented with an ACS for
the first time ever.
Current registers in Denmark do not provide informa-
tion on the clinician’s rationale for choosing a certain
dose or type of LLT. One explanation for not choosing
intensive LLT may be clinicians’ lack of knowledge of
the advantage of intensive LLT [33]. Another explan-
ation may be safety issues in older persons are of special
concern when prescribing LLT due to comorbidities and
polypharmacy [33]. In this study, three out of four pa-
tients were ≥ 60 years of age. According to treatment
guidelines, older persons are recommended to initiate
LLT in a low dose due to safety issues following up-
titration to treatment goal [3]. Yet, these recommenda-
tions are not consistent with guidelines for dyslipidemia
in ACS patients which recommend intensive LLT in all
patients presenting with ACS as soon as possible during
admission. As suggested elsewhere, alternative guidelines
for older persons with ACS aiming to address concerns
for possible medication interaction when treated with
LLT may be helpful in clinician’s decision making ensur-
ing older people optimal dyslipidemia treatment [33].
Monitoring of LDL-C levels
We observed low frequencies of lipid monitoring among
the study population. During index hospitalization less
than three out of four had lipids measured, which is in
discordance with treatment guidelines recommending all
patients to obtain lipid profile during admission. Further,
when ACS patients are discharged from the hospital
their general practitioners are informed about follow-up
and guidelines recommend re-evaluating LDL-C 4–6
Table 3 Low-density lipoprotein cholesterol (LDL-C) goal
attainment of the ACS population with at least one LDL-C
measurements during index hospitalization and alive 28 days
after index hospitalization (N = 2887) stratified by baseline
comorbidity (diabetes mellitus and/or chronic kidney disease).
LDL-C level (LDL-C < 1.8 mmol/L, LDL-C ≥ 1.8 mmol/L, no
measurement) given by number and percentage (N, %) if
nothing else is indicated (1 January 2010–31 December 2015)
Comorbidity Total ACS population, N = 2887
LDL-C (mmol/L)
< 1.8 ≥ 1.8 No
Comorbidity at inclusion (diabetes mellitus and/or chronic kidney
disease)
LDL-C measurement at
Index hospitalization 477 104 (24.2) 325 (75.8) 48
6-month follow-up 417 168 (49.7) 170 (50.3) 79
12-month follow-up 381 128 (51.8) 119 (48.2) 134
No comorbidity at inclusion
LDL-C measurement at
Index hospitalization 2410 115 (7.8) 1350 (92.2) 945
6-month follow-up 2239 684 (38.7) 1085 (61.3) 470
12-month follow-up 2164 455 (36.5) 793 (63.5) 916
ACS Acute coronary syndrome; LDL-C Low-density lipoprotein cholesterol
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weeks post index hospitalization to ensure safety issues
and to adapt LLT dose. In this study, nearly three out of
four underwent lipid testing between discharge for ACS
and 180 days after discharge. Moreover, only half of the
study population underwent LDL-C measurement be-
tween 181 days and 365 days post discharge. There is a
need to focus on follow-up and reaching targets goals in
secondary prevention management. Ensuring bilateral
communication between hospitals and primary care that
manage patients after discharge might improve this.
Study limitations
Limitations include no information on the actual con-
sumption of drugs, no information on drugs dispensed
directly to the patients in the hospital, and no reason for
drug discontinuation. The study design is an observa-
tional retrospective cohort study. However, although a
retrospective nature of the study (due to using already
collected data), data are prospectively collected in ad-
ministrative registers including hospital contacts and
diagnoses, prescription redemptions, and a laboratory
database with test results of blood samples for the study
population is used. Advantages of using these data
sources include a large sample size and no selection bias.
However, data are limited to the information and vari-
ables entered in the registers. Therefore, no information
about other important variables such as lifestyle habits
including smoking, diet and exercise was available. Fur-
thermore, no data with information about the incidence
of arterial hypertension were available for the study. Fi-
nally, inclusion of data from all laboratories in Denmark
would have strengthened the study; however, data from
one centralized laboratory can also be beneficial as it en-
sures more homogenous data with 100% comparability
without any analytical differences.
Conclusions
In this population-based cohort study, we found a con-
siderably gap between the European treatment guide-
lines and current clinical practice in patients with a first-
ever ACS diagnosis. By use of health registers and la-
boratory data it is possible to monitor clinical practice
and these findings reflect a great potential to improve
LDL-C goal attainment through optimizing current
treatment practice aiming to reduce risk of a recurrent
CV event.
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